High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age

Archives of Internal Medicine

Volumn 163, Issue 13, 2003, Pages 1549-1554

  Weverling Rijnsburger, Annelies W E ^a   Jonkers, Iris J A M ^b   Van Exel, Eric ^b   Gussekloo, Jacobijn ^b   Westendorp, Rudi G J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; AGING; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTIERELLA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037480160     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.13.1549     Document Type: Article

References (23)

1. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR, Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidermiol. 1992;2:161-176.
2. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997; 350:1119-1123.
3. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet. 2001;358:351-355.
4. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-379.
5. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
6. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J. Better outcome after stroke with higher serum cholesterol levels. Neurology. 2000;54: 1944-1949.
7. Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285:2729-2735.
8. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28:946-950.
9. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157:1305-1310.
10. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
11. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
12. von Faber M, Bootsma-van der Wiel A, van Exel E, et al. Successful aging in the oldest old: who can be characterized as successfully aged? Arch Intern Med. 2001; 161:2694-2700.
13. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Vol 1. Geneva, Switzerland: World Health Organization; 1992.
14. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15:2073-2084.
15. Nikkila M, Heikkinen J. Serum cholesterol, high-density lipoprotein cholesterol and five-year survival in elderly people. Age Ageing. 1990;19:403-408.
16. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274:539-544.
17. Sudlow CL, Warlow CP, for the International Stroke Incidence Collaboration. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. Stroke. 1997;28:491-499.
18. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality: a 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke. 1997;28:83-87.
19. Mathiesen EB, Bonaa KH, Joakimsen O. Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: the Tromsø study. Stroke. 2001;32:1960-1965.
20. Bloomfield RH, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828-2833.
21. Gordon BR, Parker TS, Levine DM, et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med. 1996; 24:584-589.
22. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA. 1993; 90:12040-12044.
23. Casas AT, Hubsch AP, Doran JE. Effects of reconstituted high-density lipoprotein in persistent gram-negative bacteremia. Am Surg. 1996;62:350-355.